fashion -WSS

fashion

author：fashion 2025-09-28 04:58:50 - browse：59548

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Latest bird flu infection made farmworker sicker than earlier cases

Wikipedia

WSS

Global childhood vaccinations edge closer to pre

Focused ultrasound for uterine fibroids: an uphill battle

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Lab trade group sues FDA to halt regulation of lab

Can CDC director Mandy Cohen drive consensus in Washington?

Mike Pence clashes with Tucker Carlson in Iowa

leisure time

fashion

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress: Eradicate hepatitis C and reduce the deficit

In age of alternative facts, a scholarly course on calling out crap

AI used to predict Covid

As demand for Covid shots wanes, Moderna seeks its next success

Antibiotic resistance nearly killed me, so I'm raising awareness of it

DIEP, the 'gold standard' of breast reconstruction, is under threat

Georgia court denies Trump's request to quash DA's 2020 election probe

Alkermes shareholders re

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

explore

Mike Pence clashes with Tucker Carlson in Iowa

Akili, maker of video game for ADHD, to be acquired for 34 million

Do more moles mean more problems? Not so, says new study

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Does aspartame cause cancer? What new WHO guidance says

Dark money group runs ads on China biotech bill

hotspot

hotspot

Wikipedia

focus